Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

ECM Weekly (29 Mar 2020) - Wuxi AppTec, Kintor Pharma, Softbank Group-Driven Placements and More!

ECM Weekly (5 Apr 2020) - Kangji Medical, WeDoctor, IDP Edu, NextDC, Coles, and More

ECM Weekly (12 Apr 2020) - Akesobio, Auckland Intl Airport, Oil Search, Flight Centre and More

Wuxi Apptec (药明康德) IPO: What You Need to Know Before the Trading Debut

Wuxi Apptec (药明康德) IPO: Pricing Update Before Book Close

WuXi Apptec (药明康德) IPO:Upside at Middle and Low End

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Wuxi Apptec is planning to sell both A-share and H-share in a private placement to raise up to USD 1.7 billion. The stock has performed well since its listing on December 13th, 2018. In this note, we will look at the proposed placement and provide our thoughts on the deal. We believe that Wuxi Apptec has strong visibility of growth driven by the CDMO/CMO segment. The placement will increase the free-float significantly and should attract large passive buying. </p>

Wuxi Apptec is planning to sell both A-share and H-share in a private placement to raise up to USD 1.7 billion. The stock has performed well since its listing on December 13th, 2018. In this note, we will look at the proposed placement and provide our thoughts on the deal. We believe that Wuxi Apptec has strong visibility of growth driven by the CDMO/CMO segment. The placement will increase the free-float significantly and should attract large passive buying. 

Wuxi Apptec (药明康德) Proposed USD1.7bn Placement: Liquidity Matters

WuXi AppTec

Wuxi Apptec (药明康德) Proposed USD1.7bn Placement: Liquidity Matters